NCT06037733Recruiting
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
Primary Tumor Radiotherapy Omitting Clinical Target Volume for Patients With Advanced Non Small Cell Lung Cancer Responded to Immunotherapy and Chemotherapy
Source: ClinicalTrials.gov · Last updated 15 Mar 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this randomized study is to investigate pneumonitis, local tumor control, and survival outcomes of primary tumor radiotherapy omitting CTV for patients with advanced NSCLC responded to immunotherapy and chemotherapy
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 134 (estimated)
- First submitted
- 7 Sept 2023
- Start date
- 13 Mar 2024
- Primary completion date
- 13 Mar 2026
- Lead sponsor
- Hubei Cancer Hospital
- Diseases
- Lung cancer
- NCT number
- NCT06037733
What you commit to
- Study type: Interventional
- Planned participants: 134
- From 13 Mar 2024 to the primary completion date, 13 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- tumor progress after therapy with immunotherapy and chemotherapy
- Previous thoracic radiotherapy;
- grade 2 or more immune-related adverse events after induction immunotherapy
Other illness
- Previous malignancies (except stage I non-melanic skin cancer or cervical carcinoma in situ);
- Have serious comorbidities, including myocardial infarction, severe arrhythmia, severe cerebrovascular disease, ulcer disease, psychosis and uncontrollable diabetes;
- Patients with HIV positive and undergoing antiviral therapy;
- Active tuberculosis
Lab values
- EGFR, ALK, or ROS1 mutation;
Other
- Pregnant or lactating women
- undergoing other clinical trials;
Who the study is looking for
- Histologically or cytologically confirmed advanced non-small cell lung cancer (according to the 8th edition of the TNM cancer staging system of AJCC and UICC);
- After over two cycles of chemotherapy combined with immunotherapy, the efficacy was CR, PR or SD (with a decreasing trend);
- Age 18 to 80 years old, performance status 0-1;
- measurable or evaluable lesions;
- Survival expectancy is not less than 6 months;
- adequate cardiac, pulmonary, renal, and hepatic and bone marrow function
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hubei Cancer Hospital Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.